Finnhub · May 15, 2026
Aspira: Q1 Earnings Snapshot
AUSTIN, Texas — AUSTIN, Texas — Aspira Women's Health Inc. on Friday reported first-quarter net income of $676,000, after reporting a loss in the same period a year earlier. The Austin,...
NASDAQ · AWH
Aspira Women's Health Inc.
Healthcare · Medical - Diagnostics & Research
$0.08
Down-$0.02 (-15.90%)
Updated Aug 22, 2026, 9:27 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.89M
- P/E ratio
- -0.28
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 443.52K
- Avg. volume
- 4.78M
Price performance
AWH price history
1M range · 0 trading sessions · Daily adjusted prices
AWH does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest AWH news
The latest Smart Investors Daily articles mentioning AWH.
Stock researchCompany · Overview
AWH research
Overview
Company profile and research snapshot.
Company profile
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $3.30
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2024 | Alliance Global Partners | Buy | — |
| Apr 10, 2024 | Cantor Fitzgerald | Neutral | — |
| Apr 1, 2024 | Cantor Fitzgerald | Neutral | — |
| Sep 26, 2023 | Cantor Fitzgerald | Neutral | — |
| Aug 22, 2023 | Alliance Global Partners | Buy | — |
News briefing
No generated briefing is available yet.
Finnhub · Apr 23, 2026
Aspira Women's Health (OTCQB: AWHL) Enters Key Growth Phase with Molecular Lab Expansion to Accelerate Breakthrough Endometriosis Blood Test ENDOinform(TM)
AUSTIN, TX / ACCESS Newswire / April 23, 2026 / Aspira Women's Health Inc. , an AI-enhanced bio-analytics company focused on the development of noninvasive gynecologic disease diagnostics and disease...
accessnewswire.com · Nov 14, 2025
Aspira Announces Third Quarter 2025 Financial Results and Provides Business Update
AUSTIN, TX / ACCESS Newswire / November 14, 2025 / Aspira Women's Health Inc. ("Aspira") (OTCQX:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announced today its results of operations for the three and nine-month periods ended September 30, 2025. September Q3 Highlights: Aspira reported relatively flat total product revenues of $2.3 million for the third quarters of 2025 and 2024.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
